A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

Inclusion Criteria: * Participant must be 18 to 50 years of age inclusive * Participants who are generally healthy as determined by medical evaluation based on screening medical history, physical examination, laboratory tests, and cardiac monitoring * Body weight of at least 50.0 kilogram (kg) for male participants or at least 45.0 kg for female participants * Body mass index (BMI) within the range of 18.0 to 28.0 kilogram per square meter (kg/m\^2) (inclusive) * Capable of giving signed informed consent * Males and females of non-childbearing potential• Exclusion Criteria: * History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data * A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug * Abnormal blood pressure (as determined by the investigator) * Symptomatic herpes zoster within 3 months prior to screening * Significant allergies to humanized monoclonal antibodies * Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions * Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the…